Biosplice Therapeutics has widely presented its science and data. Please choose the area of interest below to view a sampling of these publications.

Radiographic and Pain Outcomes from a Phase 3 Extension Study Evaluating the Safety and Efficacy of Lorecivivint in Subjects with Severe Osteoarthritis of the Knee (OA-07): 36 Month Single Blind and Placebo Crossover Phase Results

ACR 2023 | November 10 - 15, 2023

Rheumatology and Therapy | October 30, 2023

  • Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study


    Mark S. Fineman, Timothy E. McAlindon, Christian Lattermann, Christopher J. Swearingen, Sarah Kennedy, Victor A. Lopez, Ismail Simsek, Jeyanesh R. S. Tambiah, Yusuf Yazici.

Alternative Splicing Regulation as a Novel Therapeutic Target in Soft Tissue Sarcoma

American Society of Clinical Oncology (ASCO) | June 02 - 06, 2023

Ultra-selective DYRK1A inhibitors as a new therapeutic approach for the treatment of hematological malignancies  

AACR 2023 | April 14 - 19, 2023

Cancer Cell, | January 09, 2023

  • Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia

    Cancer Cell. doi:10.1016/j.ccell.2022.12.002


    Eric Wang, Jose Mario Bello Pineda, Won Jun Kim, Sisi Chen, Jessie Bourcier, Maximilian Stahl, Simon J. Hogg, Jan Phillipp Bewersdorf, Cuijuan Han, Michael E. Singer, Daniel Cui, Caroline E. Erickson, Steven M. Tittley, Alexander V. Penson, Katherine Knorr, Robert F. Stanley, Jahan Rahman, Gnana Krishnamoorthy, James A. Fagin, Emily Creger, Elizabeth McMillan, Chi-Ching Mak, Matthew Jarvis, Carine Bossard, Darrin M. Beaupre, Robert K. Bradley, and Omar Abdel-Wahab.

Structural Severity in Knee Osteoarthritis Impacts Treatment Response: A Post Hoc Pooled Analysis of Lorecivivint Clinical Trials

ACR 2022 | November 11 - 14, 2022

A Phase 2, 104-Week Study of Repeat Lorecivivint Injections Evaluating Safety, Efficacy, and Bone Health Utilizing Quantitative Computed Tomography (qCT) in Knee Osteoarthritis (OA-06)

ACR 2022 | November 11 - 14, 2022

A Phase 3, 28-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (OA-10) to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

ACR 2022 | November 11 - 14, 2022

A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial (OA-11) to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint Injected in the Target Knee Joint of Moderate to Severe Osteoarthritis Participant

ACR 2022 | November 11 - 14, 2022

Preliminary Evidence of Clinical Activity from Phase 1 and 1b Trials of the CLK/DYRK Inhibitor Cirtuvivint (CIRT) in Subjects with Advanced Solid Tumors

European Society for Medical Oncology (ESMO) | September 09 - 13, 2022

Using Pain Tolerability Thresholds to Characterize Clinically Meaningful Treatment Outcomes in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial of Intra-Articular Lorecivivint 

Osteoarthritis Research Society International (OARSI) World Congress | April 07 - 10, 2022

The American Journal of Sports Medicine | January 10, 2022

  • Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Clinical Trial of Lorecivivint

    The American Journal of Sports Medicine. doi: 10.1177/03635465211067201


    Jeyanesh R.S. Tambiah, MD, Ismail Simsek, MD, Christopher J. Swearingen, PhD, Sarah Kennedy, PhD, Brian J. Cole, MD, Timothy E. McAlindon, MD, Yusuf Yazici MD

Multigenomic characterization of context-dependent alternative splicing in normal and neoplastic cells

AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics | October 07 - 10, 2021

Evaluation of systemic pan-CLK/DYRK inhibition on organ function and tissue self-renewal

AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics | October 07 - 10, 2021

Preclinical efficacy landscape of the pan-CLK/DYRK inhibitor Cirtuvivint (SM08502)

AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics | October 07 - 10, 2021

Safety, Tolerability, and Pharmacokinetics of an Intra-articular Corticosteroid Injection Administered 7 Days Before or After Intra-articular Lorecivivint Injection into the Same Knee of Healthy Volunteers: An Open-Label, Parallel-Arm Study

World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases | August 26 - 28, 2021

Rheumatology and Therapy | June 08, 2021

  • Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial

    Rheumatology and Therapy. doi: 10.1007/s40744-021-00316-w


    Jeyanesh R. S. Tambiah, Sarah Kennedy, Christopher J. Swearingen, Ismail Simsek, Yusuf Yazici, Jack Farr & Philip G. Conaghan

A Multicenter, Observational, Extension Study Evaluating the Safety, Tolerability, and Efficacy of a Single Lorecivivint Injection in Knee OA Subjects

European League Against Rheumatism (EULAR) | June 02 - 05, 2021

Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK2/DYRK1A Inhibitor That Modulates the Wnt Pathway, Provided Cartilage-Protective Effects in an Animal Model of Post-traumatic OA

European League Against Rheumatism (EULAR) | June 02 - 05, 2021

ClinicoEconomics and Outcomes Research | May 21, 2021

  • Real-World Health Care Resource Utilization and Costs Among US Patients with Knee Osteoarthritis Compared with Controls

    ClinicoEconomics and Outcomes Research. doi: 10.2147/CEOR.S302289


    Angela V Bedenbaugh, Machaon Bonafede, Elizabeth H Marchlewicz, Vinson Lee, Jeyanesh Tambiah

Patient Characteristics and Factors Affecting Total Knee Replacement Decision-Making by Different Physician Types Treating Knee Osteoarthritis Patients

Osteoarthritis Research Society International (OARSI) Virtual World Congress | April 29 - May 03, 2021

The Patient Journey in Knee OA: Variations in Patient Characteristics and Treatment by Physician Specialty

Osteoarthritis Research Society International (OARSI) Virtual World Congress | April 29 - May 03, 2021

Initial results from a Phase 1 trial of a first-in-class pan-CDC2-like kinase inhibitor (SM08502) with proof of mechanism in subjects with advanced solid tumors

American Association for Cancer Research (AACR) Annual Meeting | April 09 - 14, 2021

Osteoarthritis and Cartilage | February 12, 2021

  • A Phase 2b Randomized Trial of Lorecivivint, a Novel Intra-articular CLK2/DYRK1A Inhibitor and Wnt Pathway Modulator for Knee Osteoarthritis

    Osteoarthritis and Cartilage. doi: 10.1016/j.joca.2021.02.004


    Yusuf Yazici, MD, Timothy E. McAlindon, MD, MPH, Allan Gibofsky, MD, JD, Nancy E. Lane, MD, Christian Lattermann, MD, Nebojsa Skrepnik, MD, PhD, Christopher J. Swearingen, PhD, Ismail Simsek, MD, Heli Ghandehari, MS, Anita DiFrancesco, BS, BA, Jamielle Gibbs, MPH, Jeyanesh Tambiah, MD, Marc C. Hochberg, MD, MPH

Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, as a Potential Treatment for Meniscal Injuries

Orthopaedic Research Society (ORS) | February 12 - 16, 2021

Journal of Orthopaedic Research | October 26, 2020

  • SM04755, a small‐molecule inhibitor of the Wnt pathway, as a potential topical treatment for tendinopathy

    Journal of Orthopaedic Research. doi: 10.1002/jor.24898


    Vishal Deshmukh, Tim Seo, Alyssa L. O'Green, Maureen Ibanez, Brian Hofilena, Sunil KC, Joshua Stewart, Luis Dellamary, Kevin Chiu, Abdullah Ghias, Charlene Barroga, Sarah Kennedy, Jeyanesh Tambiah, John Hood, Yusuf Yazici

Journal of Medical Economics | August 13, 2020

  • Health care resource utilization and burden of disease in a U.S. Medicare population with a principal diagnosis of osteoarthritis of the knee

    Journal of Medical Economics. doi: 10.1080/13696998.2020.1801453


    Fang Chen, Wenqing Su, Angela V. Bedenbaugh & Arman Oruc

SM08502, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Antitumor Effects and Wnt Pathway Inhibition in Castration-Resistant Prostate Cancer (CRPC) Models

American Association for Cancer Research (AACR) Annual Meeting | June 22 - 24, 2020

Transcriptome Analysis of TCGA Prostate Cancer Samples Identifies an Association of Poorer Survival and Aggressive Disease Biology with CDC-like Kinase (CLK) Expression and Spliceosome Regulation

American Association for Cancer Research (AACR) Annual Meeting | June 22 - 24, 2020

SM08502, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Antitumor Effects and Wnt and Cyclin D-CDK4/6-RB Pathway Inhibition in Hormone-Receptor-Positive (HR+) Breast Cancer Models

American Association for Cancer Research (AACR) Annual Meeting | June 22 - 24, 2020

Safety Profile of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis

European League Against Rheumatism (EULAR) | June 03 - 06, 2020

Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK1A Inhibitor that Modulates the Wnt Pathway, as a Potential Treatment for Meniscal Injuries

European League Against Rheumatism (EULAR) | June 03 - 06, 2020

Arthritis & Rheumatology | May 20, 2020

  • Lorecivivint, a Novel Intra‐articular CLK/DYRK1A Inhibitor and Wnt Pathway Modulator for Treatment of Knee Osteoarthritis: A Phase 2 Randomized Trial

    Arthritis & Rheumatology. doi: 10.1002/art.41315


    Yusuf Yazici, Timothy E. McAlindon, Allan Gibofsky, Nancy E. Lane, Daniel Clauw, Morgan Jones, John Bergfeld, Christopher J. Swearingen, Anita DiFrancesco, Ismail Simsek, Jeyanesh Tambiah, Marc C. Hochberg

SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor, Reduces Neuroinflammatory Responses in Mouse Models

Advances in Alzheimer’s and Parkinson’s Disease Therapies (AD/PD) Focus Meeting 2020 | April 02 - 05, 2020

Lorecivivint (SM04690), a Potential Disease-Modifying Treatment for Knee Osteoarthritis, Demonstrated Cartilage-Protective Effects on Human Osteoarthritic Explants

European Workshop for Rheumatology Research (EWRR) | February 13 - 15, 2020

SM07883, a Novel, Oral DYRK1A Kinase Inhibitor, Reduced Tau Pathology and Associated Behavioral Deficits in Preclinical Models

Tau2020 Global Conference | February 12 - 13, 2020

SM08502, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects as Monotherapy and in Combination with Chemotherapy in Triple-Negative Breast Cancer (TNBC) Models

San Antonio Breast Cancer Symposium (SABCS) | December 10 - 14, 2019

Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes

American College of Rheumatology (ACR) | November 08 - 13, 2019

The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial

American College of Rheumatology (ACR) | November 08 - 13, 2019

Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation

American College of Rheumatology (ACR) | November 08 - 13, 2019

Prospective Comparison of Sham vs. Placebo Injections: Data from a Trial of Lorecivivint, a Wnt Pathway Inhibitor for Knee Osteoarthritis

Cartilage Regeneration & Joint Preservation Society (ICRS) World Congress | October 05 - 08, 2019

Wnt Pathway Modulation via CLK2 and DYRK1A Inhibition by Lorecivivint, a Potential Disease-Modifying Treatment for Knee Osteoarthritis

Cartilage Regeneration & Joint Preservation Society (ICRS) World Congress | October 05 - 08, 2019

Cancer Letters | September 24, 2019

  • The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models

    Cancer Letters. doi:10.1016/j.canlet.2019.09.009


    Betty Y.Tam, Kevin Chiu, Heekyung Chung, Carine Bossard, John Duc Nguyen, Emily Creger, Brian W. Eastman, Chi Ching Mak, Maureen Ibanez, Abdullah Ghias, Joseph Cahiwat, Long Do, Shawn Cho, Jackie Nguyen, Vishal Deshmukh, Josh Stewart, Chiao-wen Chen, Charlene Barroga, Luis Dellamary, Sunil K. KC, Timothy J. Phalen, John Hood, Steven Cha, Yusuf Yazici

SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong inhibition of the Wnt signaling pathway and antitumor effects in diverse ovarian cancer models

American Association for Cancer Research (AACR) - Advances in Ovarian Cancer Research | September 13 - 16, 2019

Inhibition of tumor growth and post-treatment regrowth by SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, in combination with standard of care in pancreatic cancer models

American Association for Cancer Research (AACR) - Pancreatic Cancer Meeting | September 06 - 09, 2019

SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates activity against cancer stem cell (CSC)-enriched pancreatic cancer cells and suppresses stemness in vitro

American Association for Cancer Research (AACR) - Pancreatic Cancer Meeting | September 06 - 09, 2019

SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, downregulates the Wnt signaling pathway and demonstrates antitumor activity in pancreatic cancer cell lines and in vivo xenograft models

American Association for Cancer Research (AACR) - Pancreatic Cancer Meeting | September 06 - 09, 2019

Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation

Gordon Research Conference (GRC) - Wnt Signaling Networks in Development, Disease and Regeneration | August 11 - 16, 2019

Anti-inflammatory Effects of SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor in Neurodegenerative Mouse Models

Alzheimer's Association International Conference (AAIC) | July 14 - 18, 2019

Aging Cell | July 03, 2019

  • Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease

    Aging Cell. doi: 10.1111/acel.13000


    Benoît Melchior, Gopi Kumar Mittapalli, Carolyn Lai, Karen Duong‐Polk, Joshua Stewart, Bora Güner, Brian Hofilena, Amanda Tjitro, Scott D. Anderson, David S. Herman, Luis Dellamary, Christopher J. Swearingen, K.C. Sunil, Yusuf Yazici

Efficacy and Safety from a Phase 2b Trial of Lorecivivint (SM04690), a Novel Intra-articular Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee

European League Against Rheumatism (EULAR) | June 12 - 15, 2019

Comparison of Knee Osteoarthritis Treatment Patterns by Rheumatologists vs. Other Providers in a U.S. Administrative Claims Database

European League Against Rheumatism (EULAR) | June 12 - 15, 2019

Effects of SM08502, a Novel, Oral, Small-Molecule Inhibitor of Wnt Pathway Signaling, on Gene Expression and Antitumor Activity in Colorectal Cancer (CRC) Models

American Society of Clinical Oncology (ASCO) | May 31 - June 04, 2019

Osteoarthritis and Cartilage | May 24, 2019

  • Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment

    Osteoarthritis and Cartilage. doi: 10.1016/j.joca.2019.05.006


    V. Deshmukh, A.L. O'Green, C. Bossard, T. Seo, L. Lamangan, M. Ibanez, A. Ghias, C. Lai, L. Do, S. Cho, J. Cahiwat, K. Chiu, M. Pedraza, S. Anderson, R. Harris, L. Dellamary, S. KC, C. Barroga, B. Melchior, B. Tam, S. Kennedy, J. Tambiah, J. Hood, Y. Yazici

An Analysis of Treatment Patterns in Knee Osteoarthritis in a U.S. Administrative Claims Database

International Society for Pharmaeconomics and Outcomes Research (ISPOR) | May 18 - 22, 2019

A small-molecule Wnt pathway modulator (SM04554) as a potential topical treatment for androgenetic alopecia

International Dermatology and Cosmetology Congress (INDERCOS) | March 27 - 30, 2019

An Analysis of the Burden of Illness and Treatment in Knee Osteoarthritis in a U.S. Administrative Claims Database

Academy of Managed Care Pharmacy (AMCP) | March 25 - 28, 2019

A 52-Week, Randomized, Double-Blind, Phase 2 Study of an Intra-articular Wnt Pathway Inhibitor (SM04690) for Osteoarthritis

American Academy of Orthopaedic Surgeons (AAOS) | March 12 - 16, 2019

SM04690, a Potential Disease-Modifying Treatment for Knee Osteoarthritis, Functions Through Inhibition of CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation

Orthopaedic Research Society (ORS) | February 02 - 05, 2019

Efficacy and Safety from a Phase 2b Trial of SM04690: A Novel, Intra-Articular Wnt Pathway Inhibitor for the Treatment of Knee Osteoarthritis

International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit | January 17 - 18, 2019

Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee

American College of Rheumatology (ACR) | October 19 - 24, 2018

Assessment of Health-Related Quality of Life in a 52-Week, Phase 2, Randomized, Controlled Trial of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Treatment of Knee Osteoarthritis

American College of Rheumatology (ACR) | October 19 - 24, 2018

Results from a 52-week, phase 2a study of an intra-articular, small molecule Wnt pathway inhibitor, SM04690, for knee osteoarthritis

Asia Pacific League of Associations for Rheumatology (APLAR) | September 06 - 09, 2018

Tau Pathology Reduction with SM07883, a Novel, Potent, and Selective Oral DYRK1A Inhibitor - a Potential Therapeutic for Alzheimer’s Disease

Alzheimer’s Association International Conference (AAIC) | July 22 - 26, 2018

Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52 week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor

European League Against Rheumatism (EULAR) | June 13 - 16, 2018

Potential Nociceptive Pain Relief of Intra-Articular Saline Control in Clinical Trials of Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Trials

European League Against Rheumatism (EULAR) | June 13 - 16, 2018

Radiographic outcomes were associated with pain and function responses: post-hoc analysis from a phase 2 study of a Wnt pathway inhibitor, SM04690, for knee osteoarthritis treatment

European League Against Rheumatism (EULAR) | June 13 - 16, 2018

Radiographic Outcomes Were Concordant with Outcome Measures in Rheumatology Osteoarthritis Research Society International (OMERACT-OARSI) Strict Response: Post-Hoc Analysis from a Phase 2 Study of a Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis Treatment

Osteoarthritis Research Society International (OARSI) World Congress | April 26 - 29, 2018

Joint Space Width Inclusion Criteria Can Reduce Knee Osteoarthritis Trial Heterogeneity: Post-Hoc Data from a Phase 2 Trial of Wnt Pathway Inhibitor, SM04690

Osteoarthritis Research Society International (OARSI) World Congress | April 26 - 29, 2018

SM04690, a small molecule Wnt pathway inhibitor, appeared to have no deleterious effects on bone, joint, and tissue health in knee OA models

World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases | April 19 - 22, 2018

SM04690 caused dose-dependent Wnt pathway modulation within a homeostatic range in a rat model of knee osteoarthritis

World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases | April 19 - 22, 2018

SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models

International Cartilage Repair Society (ICRS) | April 09 - 12, 2018

Radiographic Outcomes Were Concordant with Pain and Function Response: Post-Hoc Analysis from a Phase 2 Study of SM04690, a Wnt Pathway Inhibitor for Knee Osteoarthritis Treatment

International Cartilage Repair Society (ICRS) | April 09 - 12, 2018

Joint Space Width Criteria Can Reduce Knee OA Trial Heterogeneity: P2 Post-Hoc Data from Wnt Pathway Inhibitor, SM04690

International Cartilage Repair Society (ICRS) | April 09 - 12, 2018

A 52 Week Randomized, Double-Blind Phase 2 Study of Intra-Articular, Wnt Pathway Inhibitor (SM04690) for Osteoarthritis

International Cartilage Repair Society (ICRS) | April 09 - 12, 2018

Results from a 52 Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis

American College of Rheumatology (ACR) | November 03 - 08, 2017

Reducing Heterogeneity in OA Clinical Trials: Data from a Phase 2 Study of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor in Knee Osteoarthritis

American College of Rheumatology (ACR) | November 03 - 08, 2017

Osteoarthritis and Cartilage | September 15, 2017

Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

Gordon Research Conference: Wnt Signaling | August 06 - 11, 2017

Osteoarthritis and Cartilage | July 13, 2017

  • A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

    Osteoarthritis and Cartilage, 25(10), 1598-1606. doi: 10.1016/j.joca.2017.07.006


    Y. Yazici, T.E. McAlindon, R. Fleischmann, A. Gibofsky, N.E. Lane, A.J. Kivitz, N. Skrepnik, E. Armas, C.J. Swearingen, A. DiFrancesco, J.R.S. Tambiah, J. Hood, M.C. Hochberg

  • Related Review: Osteoarthritis in 2017: Latest advances in the management of knee OA

Cartilage Regeneration in a Rat Model of Knee OA by SM04690, a Potential Disease Modifying Wnt Pathway Inhibitor

International Cartilage Repair Society Heritage Summit | June 29 - July 01, 2017

Radiographic Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Week 26 Interim Analysis

European League Against Rheumatism (EULAR) | June 14 - 17, 2017

Clinical Outcomes from a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Injectable, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis: Week 26 Interim Analysis

European League Against Rheumatism (EULAR) | June 14 - 17, 2017

Health Care Resource Use of Medicare Beneficiaries With Primary Osteoarthritis (OA) Of The Knee – A Claims Data Analysis

International Society for Pharmacoeconomics and Outcomes (ISPOR) | May 20 - 24, 2017

A Statistical Analysis Plan to Understand Osteoarthritis Patient Journey by Linking Medicare Claims Across Care Delivery Settings

International Society for Pharmacoeconomics and Outcomes (ISPOR) | May 20 - 24, 2017

Anti-inflammatory Properties of SM04690, a Small Molecule Inhibitor of the Wnt Pathway as a Potential Treatment for Knee Osteoarthritis

Osteoarthritis Research Society International (OARSI) | April 27 - 30, 2017

A Small Molecule Modulator of the Wnt Pathway (SM04554) as a Potential Topical Treatment for Androgenetic Alopecia (AGA)

Society for Investigative Dermatology (SID) | April 26 - 29, 2017

Safety and Biopsy Outcomes of a Topical Treatment (SM04554) for Male Androgenetic Alopecia (AGA): Results from a Phase 2, Multicenter, Randomized, Double-blind, Vehicle-controlled Trial

American Academy of Dermatology (AAD) | March 03 - 07, 2017

A Small Molecule, SM04690, has Inhibitory Effects on the Wnt Pathway and Inflammation In Vitro, With Potential Implications For the Treatment of Osteoarthritis

American College of Rheumatology (ACR) | November 11 - 16, 2016

OMERACT-OARSI ‘Strict Responders’ Analysis from Results of a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of a Novel, Intra-Articular, Injectable Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee

Osteoarthritis Research Society International (OARSI) | March 31 - April 03, 2016

Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

Osteoarthritis Research Society International (OARSI) | March 31 - April 03, 2016

Safety, Tolerability and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia (AGA): Results from a Phase 2 Trial

American Academy of Dermatology (AAD) | March 04 - 08, 2016

Safety and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia (AGA): Results from a Phase 1 Trial

World Congress for Hair Research (WCHR) | November 18 - 21, 2015

Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

American College of Rheumatology (ACR) | November 06 - 11, 2015

Magnetic Resonance Imaging Outcomes Using an Intra-Articular Injection (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study

American College of Rheumatology (ACR) | November 06 - 11, 2015

Discovery of an Intra-Articular Injection Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Disease Modifying Treatment for Knee Osteoarthritis

American College of Rheumatology (ACR) | November 06 - 11, 2015

Award Winning

Privacy Policy Terms of Use Contact Us © Biosplice Therapeutics, Inc. All rights reserved.